Empagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), is a novel diabetic medication that reduces the risk of progression of chronic kidney disease (CKD) and heart failure and improves exercise tolerance regardless of the diabetes status. One of the important ways that empagliflozin improves health may be through its benefits on blood vessels. The effects of empagliflozin on blood vessels and physical function have not been examined in patients with chronic kidney disease, and it is less clear if empagliflozin may be beneficial in patients with chronic kidney disease without heavy urinary protein leakage.

The investigators will examine if empagliflozin can improve blood vessel function and exercise tolerance in Veterans with chronic kidney disease without heavy urinary protein leakage.

Investigators hope to learn which strategies work best to help Veterans who are not benefiting from their first PTSD treatment or not completing between-session homework assignments regularly that might improve treatment response. The investigators also want to learn how best to match the right type and amount of treatment to each individual Veteran.

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.

This is a study to evaluate the efficacy and safety of AZD0780 in adults with clinical ASCVD or who are at risk for a first ASCVD event and who have elevated LDL-C. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood.

This is a Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function.

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps (FORTE) is a colorectal cancer prevention study looking to answer the question: when should patients who had 1-2 small benign polyps (adenomatous polyps/adenomas) removed during colonoscopy have repeat surveillance colonoscopy?

This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone.

The purpose of the study is to compare the subcutaneous (SC) injection using an investigational wearable injector device to intravenous (IV) infusion of isatuximab in combination with pomalidomide and dexamethasone for patients with relapsed/refractory multiple myeloma (RRMM).

This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone [R-miniCHOP]) versus R-miniCHOP alone in treating patients 75 years or older with newly diagnosed diffuse large B cell lymphoma.

The Diet study will determine the effectiveness of two diets utilizing FODMAP (Fermentable Oligo-, Di- and Mono-saccharides and Polyols) carbohydrates.

The Preventable study is investigating the role of statins in older adults, to determine the risk/benefit for prevention of cardiovascular disease or dementia at baseline, and to see if statins may reduce death, dementia, and persistent disability, mild cognitive impairment and dementia, and cardiovascular events.